Skip to NavigationSkip to content

Allergan's atogepant fulfils primary endpoint in episodic migraine

Published on 12/06/18 at 10:38am

Allergan has made ground in its quest to become “the headache company” with the release of new Phase 2b/3 data for its oral calcitonin gene-related peptide (CGRP) receptor antagonist atogepant, showing that the therapy met its primary endpoints for episodic migraine across all treatment arms and five different dosing regimens.

Across the 795 trial participants, atogepant demonstrated a “statistically significant” reduction from baseline in monthly migraine/probable migraine (MPM) headache days compared to placebo after 12 weeks of treatment. The drug’s safety profile was found to be in line with the effects shown by the placebo.

"These exciting results demonstrate the potential for atogepant for a broad spectrum of migraine patients. The efficacy and safety across doses and dose regimens show promise in a patient population with high unmet treatment needs," said Dr. Peter Goadsby, Neurologist and Professor at Kings College, London and University of California, San Francisco. "Results from this atogepant trial provide continued evidence for the clinical potential of oral CGRP antagonists and the substantial value of progressing research and developing new treatments for migraine patients."

Allergan Chief Commercial Officer Bill Meury added: “The positive results from this study show that oral atogepant has a compelling profile relative to other treatment options on the market and in development for the prevention of migraine. We are excited about the prospects for this product and rapidly moving to the next stage of development. Allergan has one of the most innovative and deepest product lines for migraine in the industry, with Botox approved for the prevention of chronic migraine and oral atogepant and ubrogepant in development for the prevention and acute treatment of migraine.”

The company confirmed it will now speak to regulatory authorities around the world before pursuing further Phase 3 trials.

Matt Fellows


I am very happy to read this. Appreciate your sharingVery interesting! Thanks you 

I am very happy to read this. Appreciate your sharing

Very interesting! Thanks you 


Draw My Thing

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches